Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses the use of advanced error-corrected DNA sequencing for the highly sensitive detection of measurable residual disease (MRD). Next-generation sequencing introduces errors, which this ‘next next-generation sequencing’ method corrects for. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
